Condition
Iritis
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
60%
3 of 5 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 2 (1)
Trial Status
Completed5
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02416128Not ApplicableWithdrawnPrimary
Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology
NCT01154010Not ApplicableCompleted
PEMF: an Adjunct Therapy for Anterior Uveitis
NCT00001734Completed
Screening for NEI Clinical Studies
NCT00006188Completed
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00476593Not ApplicableCompleted
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
NCT00130637Phase 2Completed
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Showing all 6 trials